|
|
6707, Democracy Blvd., Suite 505
Bethesda, MD 20817 USA
phone:(240) 752-1420
fax:(240) 752-1425
|
|
| Symbol |
MITI |
| Exchange |
Nasdaq |
| Founded |
1993 |
| Employees |
|
|
|
| www.micromet.de
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Novel antibody derived therapeutics. |
|
| Management |
| Christian Itin, PhD, President, Chief Executive Officer and Director; Barclay Phillips, Senior Vice President and Chief Financial Officer; Patrick A. Baeuerle, PhD, Professor for Immunology, Senior Vice President and Chief Scientific Officer; Jan Fagerberg, M.D., Senior Vice President and Chief Medical Officer; Jens Hennecke, PhD, Senior Vice President Business Development |
| |
|
|
|
|
|
|
|
| Keywords |
| sanofi-aventis, medimmune, merck serono, morphotek, nycomed |
|
|
|
| Description |
|
Micromet, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer and inflammatory and autoimmune diseases. |
|
| Products / Services |
A pipeline of drugs to treat cancer, inflammation, and autoimmune disorders.
|
|
| Technology / Differentiation |
| BiTE antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell attacks. These cytolytic synapses mediate the delivery of cytotoxic proteins called perforin and granzymes from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios of T cells to target cells. |
|
|
| Strategy |
Micromet, Inc. was formed in May 2006 through the merger of CancerVax Corporation and Micromet AG, a privately held German company. ==The cCompany has strategic collaborations with Serono, MedImmune, Inc., and Enzon Pharmaceuticals, Inc.
|
|
| Status |
| The company currently has two drug candidates, adecatumumab (MT201) and MT103/MEDI-538, in clinical trials against three major cancer indications: prostate cancer, metastatic breast cancer and relapsed non-Hodgkin's lymphoma (NHL). In addition, Micromet?s pipeline covers four preclinical drug candidates and several compounds at research stage. |
|
|
Additional Information |
| On May 5, 2006, CancerVax, Inc. (formerly NASDAQ: CNVX) completed a merger with Micromet AG, or Micromet, a privately-held German company, pursuant to which CancerVax's wholly owned subsidiary, Carlsbad Acquisition Corporation, merged with and into Microm |
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
